



Correction: Summary of capital reduction pursuant to Article 32 of the Danish Capital Markets Act

With reference to company announcement no. 5/2019 a correction to the total number of voting rights in the company is hereby announced. Following the capital reduction announced in company announcement no. 4/2019, the total capital stock of Novozymes, as of March 29, 2019, consists of nominally DKK 582,000,000, of which DKK 107,487,200 are related to A shares and DKK 474,512,800 are related to B shares, divided into 291,000,000 shares, corresponding to 53,743,600 A shares and 237,256,400 B shares with a nominal value of DKK 2 each and a total of 1,549,384,800 voting rights.

September 16, 2019
Company announcement No.35

Contact information
novozymesIR@novozymes.com

Tobias Cornelius Björklund
+45 3077 8682
tobb@novozymes.com

Carl Ahlgren
+45 3077 2783
cxal@novozymes.com

About Novozymes

Novozymes is the world leader in biological solutions. Together with customers, partners and the global community, we improve industrial performance while preserving the planet's resources and helping build better lives. As the world's largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel and many other benefits that we rely on today and in the future. We call it Rethink Tomorrow. www.novozymes.com

Novozymes A/S CVR number: 10 00 71 27 LEI: 529900TGWNZXD2R3JW38

Rethink Tomorrow

Novozymes A/S
Krogshøjvej 36
2880 Bagsvaerd
Denmark

Phone: +45 4446 0000

novozymes® 